Number

Percentage

Patients

100

AGE OF THE SUBJECTS

Age <45

36

36%

Age >45

64

64%

GENDER OF THE SUBJECTS

Males

65

65%

Female

35

35%

STAGE OF THE DISEASE

CP-CML

48

48%

AP-CML

28

28%

BC-CML

24

24%

TYPE OF BCR-ABL TRANSCRIPTS

A2b2

31

31%

A2B3

67

67%

A2b2/ A2b3

2

2%

MOLECULAR  RESPONSES TO  IMATINIB

MMR

52

52%

No MR

48

48%

HEMATOLOGICAL RESPONSES TO  IMATINIB

MHR

50

50%

Minor HR

10

10%

Loss HR

40

40%

TYROSINE KINASE INHIBITOR THERAPY

Imatinib

90

90%

Imatinib

7

7%

Interferon

3

3%

THROMBOCYTOPENIA

Thrombocytopenia

60

60%

No Thrombocytopenia

40

 40%